FR 180204 is a potent, selective, ATP-competitive ERK inhibitor with Ki of 0.31 and 0.14 uM for ERK1 and ERK2, respectively.
FR 180204 inhibits TGFβ-induced luciferase-expression in mink lung epithelial Mv1Lu cells.
FR 180204 decreases plasma anti-CII antibody levels and attenuates delayed-type hypersensitivity in CII-immunized DBA/1 mice, also inhibits in vitro CII-induced proliferation of lymph node cells prepared from CII-immunized mice.
FR 180204 enhances apoptotic and anti-proliferative effects of Akt inhibitor API-1 in human DLD-1 and LoVo colorectal cancer cells.
